Multiple Myeloma Vaccination Patterns in a Large Health System: A Pilot Study

Alemu, Andinet; Singh, Maharaj; Blumberg, Chris; Richards, John O.; Oaks, Martin K.; Thompson, Michael A.

doi:10.17294/2330-0698.1415

Cited by 12 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients’ compliance with their physicians’ advice was remarkably high with good compliance rates (greater than 80%) for influenza, pneumococci, hepatitis B, and DTP. The rates of recommendations for influenza and pneumococci were higher than reported in a previous study for US myeloma patients 4 and supported by clinical experience and data showing that upper and lower respiratory tract infections are the most frequently observed infectious complications in patients with MM. 1 Upper respiratory tract infections disturb the complex equilibrium between commensal bacteria and viruses and facilitate the development of lower respiratory tract bacterial and viral infections, 5 underlining the need for applying the available prevention strategies.…”

supporting

confidence: 75%

Compliance With Vaccination Recommendations Among Patients With Multiple Myeloma: A Real World Experience

Ludwig¹,

Meckl²,

Engelhardt

2021

HemaSphere

View full text Add to dashboard Cite

supporting

confidence: 75%

Compliance With Vaccination Recommendations Among Patients With Multiple Myeloma: A Real World Experience

Ludwig¹,

Meckl²,

Engelhardt

2021

HemaSphere

View full text Add to dashboard Cite

“…Infections remain the most common cause of morbidity and mortality in multiple myeloma besides the disease itself [ 1 , 2 ]. The risk of infection is increased already at the stage of MGUS [ 3 ], and is even higher in patients with active disease when starting anti-myeloma therapy.…”

Section: Introductionmentioning

confidence: 99%

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Ludwig¹,

et al. 2020

View full text Add to dashboard Cite

Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased risk of infections due to the diseaseinherent immune suppression, and because of the immune suppressive effects of therapy. Hence, all appropriate measures should be exploited, to elicit an effective immune response to common pathogens like influenza, pneumococci, varicella zoster virus, and to those bacteria and viruses (haemophilus influenzae, meningococci, and hepatitis) that frequently may pose a significant risk to patients with multiple myeloma. Patients after autologous, and specifically after allogeneic transplantation have severely reduced antibody titers, and therefore require a broader spectrum of vaccinations. Response to vaccination in myeloma often is less vigorous than in the general population, mandating either measurement of the postvaccination antibody titers and/or repeating the vaccination. Here, we compile the existing data on vaccination in multiple myeloma and provide recommendations for clinical practice.

show abstract

“…One small retrospective American study with 411 MM patients from 2012 to 2014 found that 58% had received at least one SP vaccine [ 28 ]. To our knowledge, this is the only other study of vaccination rates in MM patients.…”

Section: Discussionmentioning

confidence: 99%

Vaccination during the First Diagnosis of Multiple Myeloma: A Cohort Study of the French National Health Insurance Database

et al. 2020

View full text Add to dashboard Cite

Purpose: Infections are frequent and often result in serious complications in patients with multiple myeloma (MM). Prophylactic vaccination is recommended for influenza virus, Streptococcus pneumoniae (SP), and Hemophilus influenzaeb (Hib). The aims of this study were to measure the vaccination rates within 24 months after the diagnosis of multiple myeloma and to identify factors associated with vaccine use. Methods: MM patients were selected through the French national health insurance database from 1 January 2010 to 31 December 2015. Patients with a previous history of MM were excluded. Results: Vaccination rates against influenza, SP, and Hib among 22,831 newly diagnosed MM patients were, respectively, 28.5%, 10.3%, and 1.4%. Only 0.7% received all three vaccines. Factors associated with vaccination were young age, male gender, an absence of comorbidity, a history of higher medication and vaccine consumption, Herpes simplex virus (HSV), Varicella zoster virus (VZV), and the use of pneumocystis prophylaxis. Conclusion: The low rates of vaccination indicate the need to improve physician and MM patient adherence and education regarding vaccination.

show abstract

Multiple Myeloma Vaccination Patterns in a Large Health System: A Pilot Study

Cited by 12 publications

References 27 publications

Compliance With Vaccination Recommendations Among Patients With Multiple Myeloma: A Real World Experience

Compliance With Vaccination Recommendations Among Patients With Multiple Myeloma: A Real World Experience

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Vaccination during the First Diagnosis of Multiple Myeloma: A Cohort Study of the French National Health Insurance Database

Contact Info

Product

Resources

About